|
Dr. Martin Adelmann
Ms. Raquel Cabana
Dr. L. Scott Cram
Dr. Madhu Dikshit
Dr. Sumeet Gujral
Mr. Michael Keeney
Dr. Awtar Krishan
Dr. Mike Ormerod
Dr. Vincent Shankey
Dr. Arvinder Singh
Dr. Ranbir Sobti
Dr. Vivek Tanavde
Dr. William G. Telford
Dr. Rakesh Singal
Mrs. Veena Kapoor
Mr. Ron Hamelik
|
 Core Faculty
Michael Keeney
Michael Keeney received his Fellowship, Institute of Medical Laboratory Sciences, in Hematology in Scotland. Since 1992 Mike has worked as the Technical Specialist of Hematolgy/Flow Cytometry at the London Health Sciences Centre in London, Ontario and Associate Scientist with the Lawson Health Research Institute. He is currently Vice-Chairman of the Hematology Committee for QMP-LS, and is also a consultant for the College of American Pathologists, Diganostic Immunology Resource Committee. Mike is a reviewer for Cytometry and Clinical Cytometry and also sits on the editorial board. Major research interest: Rare event analysis. In collaboration with Rob Sutherland from Toronto and Jan Gratama from the Netherlands, a clinical guideline for CD34 enumeration in hematopoietic stem cell transplantation was developed, which is now the most commonly used method for assessing mobilization and graft adequacy. The method is known as the ISHAGE guideline
Lecture
Lecture: Role of CD34 enumeration in hematopoietic stem cell transplantation
Studies dating back to the early 1990s show that rare event detection was difficult for routine clinical laboratories to perform with any degree of accuracy. Around the mid 1990's two main methods of CD34 enumeration were developed, the ISHAGE guidelines for CD34 and ProCOUNTTM, a commercial product that standardized both the preparation and analysis of CD34 cells in fresh blood and fresh apheresis products. As the demands for more sophisticated analysis and accurate enumeration of CD34+ cells in a wider variety of sources of stem cells (cord blood, manipulated and post-thawed samples) increased, a single platform variant of the ISHAGE method was developed to directly enumerate the number of viable CD34+ cells per microlitre. Currently, the ISHAGE gating strategy (or its commercial variant, StemKITTM , the single platform ISHAGE method) have become the most utilized methods in both North America and beyond. Quality assurance studies over the last several years have shown that the level of standardization achievable by these methods has reached the point where a C.V. of 10% is readily achievable, both between and within different laboratories. This lecture will review current indications for transplant and the role of CD34 enumeration in both the autologous and allogeneic setting.
Relevant Literature
Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee IH. The ISHAGE Guidelines for CD34+ Cell Determination by Flow Cytometry. J Hematotherapy 1996, 5:213-226
Keeney M, Chin-Yee IH, Weir K, Popma J, Nayar R, Sutherland DR. Single Platform Flow Cytometric Absolute CD34+ Cell Counts Based On The ISHAGE Guidelines. Cytometry (Communications in Clinical Cytometry) 34:61 70, 1998
Gratama JW, Kraan J, Keeney M, Sutherland DR, Granger V, Barnett D. Validation of the single-platform ISHAGE method for CD34+ hematopoietic stem and progenitor cell enumeration in an international multicenter study. Cytotherapy (2003) Vol. 5, 55-65
Allan, A.L., Vantyghem, S.A., Tuck, A.B., Chambers, A.F., Chin-Yee, I., and Keeney, M. (2005). Detection and quantification of circulating tumor cells in mouse models of human breast cancer using immunomagnetic enrichment and multiparameter flow cytometry. Cytometry 2005 May; 65A (1):4-14.
| |
